| This is the first economic evaluation of nivolumab for patients with advanced non-small cell lung cancer (aNSCLC) in China based on individual patient-level data. |
| Nivolumab was associated with survival and quality-adjusted survival benefits versus docetaxel for treatment of aNSCLC. |
| Treatment with nivolumab is anticipated to provide value to the Chinese healthcare system and direct healthcare benefits to Chinese patients with aNSCLC. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.